A5029733252- Rheumatoid Arthritis Research and Therapies
- Monoclonal and Polyclonal Antibodies Research
- Systemic Lupus Erythematosus Research
- Chronic Lymphocytic Leukemia Research
- SARS-CoV-2 and COVID-19 Research
- Immunodeficiency and Autoimmune Disorders
- Spondyloarthritis Studies and Treatments
- Biosimilars and Bioanalytical Methods
- Autoimmune and Inflammatory Disorders Research
- COVID-19 Clinical Research Studies
- Lymphoma Diagnosis and Treatment
- Inflammatory Bowel Disease
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Psoriasis: Treatment and Pathogenesis
- Peripheral Neuropathies and Disorders
- Long-Term Effects of COVID-19
- Cell Adhesion Molecules Research
- Autoimmune Bullous Skin Diseases
- Multiple Sclerosis Research Studies
- Complement system in diseases
- Microscopic Colitis
- Pharmaceutical studies and practices
- Immune Response and Inflammation
- Blood properties and coagulation
Reade
2016-2025
Sanquin
2016-2025
University of Amsterdam
2015-2024
Amsterdam UMC Location Vrije Universiteit Amsterdam
2007-2024
Amsterdam University Medical Centers
2007-2024
Amsterdam UMC Location University of Amsterdam
2014-2024
Center for Rheumatology
2015-2024
Bipar
2022-2024
King's College London
2023
Hacettepe University
2023
<b>Background:</b> A substantial proportion of patients with rheumatoid arthritis (RA) do not respond, or lose initial response, to adalimumab treatment. One explanation for non-response is that develop anti-adalimumab antibodies. <b>Objectives:</b> To evaluate the incidence formation antibody against and association serum concentrations clinical response. <b>Methods:</b> In a cohort 121 consecutive RA treated adalimumab, antibodies were measured together response variables before up 28...
Abstract Objective To investigate the safety and efficacy of B cell depletion treatment patients with active primary Sjögren's syndrome short duration (early SS) SS mucosa‐associated lymphoid tissue (MALT)–type lymphoma (MALT/primary SS). Methods Fifteen were included in this phase II trial. Inclusion criteria for early group hyperactivity (IgG >15 gm/liter), presence autoantibodies (IgM rheumatoid factor, anti‐SSA/SSB), disease (<4 years). MALT/primary an associated MALT‐type (Ann...
Abstract Objective Treatment of patients with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, may result in the formation infliximab‐specific IgG antibodies. This study evaluated clinical significance these antibodies rheumatoid arthritis (RA). Methods Antiinfliximab were measured using newly developed radioimmunoassay cohort 51 consecutive RA treated followup 1 year. In addition, serum infliximab levels determined by enzyme‐linked immunosorbent assay. The...
Background Rises in circulating C-reactive protein (CRP), the prototypical acute-phase humans, correlate with clinical outcome patients myocardial ischemia and infarction. We hypothesized that these correlations might reflect active participation of CRP local inflammatory response ensuing jeopardized myocardium because on binding to a ligand, is able activate classic pathway complement, addition, complement activation has been shown occur locally infarcted myocardium. Methods Results To...
Immunoglobulin G (IgG) antibodies are crucial for protection against invading pathogens. A highly conserved N-linked glycan within the IgG-Fc tail, which is essential IgG function, shows variable composition in humans. Afucosylated variants already used anticancer therapeutic their increased activity through Fc receptors (FcγRIIIa). Here, we report that afucosylated (approximately 6% of total humans) specifically formed enveloped viruses but generally not other antigens. This mediates...
Patients diagnosed with coronavirus disease 2019 (COVID-19) become critically ill primarily around the time of activation adaptive immune response. Here, we provide evidence that antibodies play a role in worsening at seroconversion. We show early-phase severe acute respiratory distress syndrome 2 (SARS-CoV-2) spike protein-specific immunoglobulin G (IgG) serum COVID-19 patients induces excessive inflammatory responses by human alveolar macrophages. identified this response is dependent on...
Data are scarce on immunogenicity of COVID-19 vaccines in patients with autoimmune diseases, who often treated immunosuppressive drugs. We aimed to investigate the effect different drugs antibody development after vaccination diseases.In this study, we used serum samples collected from diseases and healthy controls were included two ongoing prospective cohort studies Netherlands. Participants eligible for inclusion substudy if they had been vaccinated any vaccine via Dutch national...
Background Anti-citrullinated protein antibodies (ACPA) are associated with increased risk for rheumatoid arthritis. Objective To investigate the effect of presence and levels ACPA on arthritis development in patients arthralgia. Methods Patients arthralgia positive or IgM factor (IgM-RF) were tested shared epitope (SE) prospectively followed up at least 12 months. Absence clinical inclusion during follow-up independently confirmed by two investigators. Cox regression hazard analyses used to...
The in vivo function of C-reactive protein (CRP) is unknown. Among the vitro functions assigned to CRP ability activate complement via classical pathway. To date, there no evidence supporting that exerts this vivo. We here show a novel approach assess CRP-mediated activation vivo, which based on property activated factors C3 and C4 fix during induced by acute phase protein. developed specific ELISAs for complexes between C4b, C4d, C3b, or C3d. established complement-CRP were formed only...
<h3>Objective</h3> To investigate how antibodies against anti-tumour necrosis factor (anti-TNF) agents influence response after switching from infliximab to adalimumab in rheumatoid arthritis (RA). <h3>Methods</h3> This cohort study consisted of 235 patients with RA, all treated adalimumab. At baseline 52 (22%) had been previously ('switchers'), and 183 (78%) were anti-TNF naive. Disease activity (using the 28-joint count Activity Score (DAS28)) presence assessed. Clinical was compared...
<b>Objective:</b> To investigate the relationship between serum trough infliximab levels and clinical response to treatment in patients with rheumatoid arthritis (RA). <b>Methods:</b> Disease activity before 2, 6, 14 weeks after initiation of at a dose 3 mg/kg cohort 105 RA were assessed. Serum responders non-responders compared. Additionally, responses high, intermediate, low <b>Results:</b> After had lower than (median (interquartile range) 0.5 (0.2–2.2) <i>v</i> 3.6 (1.4–8.2) mg/l;...
Adalimumab is an effective treatment in patients with Crohn's disease; as it a humanized anti-tumour necrosis factor monoclonal antibody, immunogenicity thought not to be of any significance.To assess whether antibodies adalimumab (ATAs) affect outcome disease previously treated infliximab.A retrospective study was performed. Patients active and who had lost response or were intolerant infliximab adalimumab. Clinical side effects assessed serum ATAs (ATIs).In total 30 [M/F (7/23)], median...
To examine how anti-citrullinated protein antibody (ACPA) epitope spreading takes place prior to the onset of clinical rheumatoid arthritis (RA), and analyze pattern autoantigen reactivity at beginning immune response.Multiple consecutive serum samples from 79 RA patients who had donated blood before disease were available for analysis. Fifty-three tested positive ACPAs RA. For these patients, a median 6 (interquartile range 4-9) sequential pre-RA obtained 1-2 years apart tested. Reactivity...
<h3>Objectives</h3> Millions of patients worldwide are treated with therapeutic monoclonal antibodies. These biological therapeutics can be immunogenic, resulting in anti-drug antibody formation which leads to loss response. Fully human agents, such as the anti-tumour necrosis factor α (anti-TNFα) adalimumab, considered weakly but anti-adalimumab antibodies (AAA) were recently detected more than half rheumatoid arthritis (RA) within 28 weeks treatment. A study was undertaken determine...
<h3>Objective</h3> To determine a concentration–effect curve of adalimumab in rheumatoid arthritis (RA) patients taking into account the effect methotrexate (MTX) on concentration and to identify therapeutic range for concentrations. <h3>Methods</h3> In prospective observational cohort study, 221 consecutive with RA were treated 40 mg subcutaneously every other week. The relationship between trough level clinical efficacy after 28 weeks follow-up was determined curve. A receiver–operator...